Submit written requests for a single copy of the guidance document entitled, “Guidance on Withdrawal of Subjects From Research: Data Retention and Other Related Issues,” to the Division of Policy and Assurances, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852. FDA’s guidance entitled, “Guidance for Sponsors, Clinical Investigators, and IRBs: Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials” can be found at http://www.fda.gov/downloads/regulatoryinforamtion/guidances/ucm126489.pdf. endstream
endobj
If a subject decides to withdraw from all components of a research study, the investigator must discontinue all of the following research activities involving that subject’s participation in that study (45 CFR 46.116(a)(8)): Sometimes, a subject wants to withdraw from the primary interventional component of a study, but is willing to allow the investigator to continue other research activities described in the IRB-approved protocol and informed consent document that involve participation of the subject, such as: (1) obtaining data about the subject through interaction with the subject (e.g., through follow-up interviews, physical exams, blood tests, or radiographic imaging); or (2) obtaining identifiable private information from the subject’s medical, educational, or social services agency records or from the subject’s healthcare providers, teachers, or social worker. Informed consent documents provide information to research subjects to ensure they can understand the research and make an informed, voluntary decision whether to participate. FDA has issued a related guidance document entitled “Guidance for Sponsors, Clinical Investigators, and IRBs: Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials” (see http://www.fda.gov/downloads/regulatoryinforamtion/guidances/ucm126489.pdf). "The right to withdraw from participation in research is recognized in virtually all national and international guidelines for research on human subjects. For example, consider an IRB-approved clinical trial testing the safety and effectiveness of an experimental chemotherapy regimen in patients with lung cancer that involves the following sequential procedures for each subject: If a subject informs the investigator that he or she wishes to withdraw from the clinical trial after the second monthly cycle of the experimental chemotherapy regimen because of unacceptable side effects, the investigator may ask the subject if he or she is willing to undergo the follow-up CT scans, interviews, and physical examinations that were described in the IRB-approved protocol and in the informed consent document signed by the subject. Thus, for HHS-conducted or –supported research that is also regulated by FDA, compliance with FDA’s requirements regarding data retention when subjects withdraw from the research will not result in any noncompliance with the provisions of HHS regulations for the protection of human subjects (45 CFR part 46) related to discontinuation of subject participation. An unscrupulous researcher could use this asymmetry to mislead subjects about the level of risk in a study. For HHS-conducted or –supported research that is also FDA-regulated, regardless of whether the research is subject to the HIPAA Privacy Rule, the investigator should inform subjects that data collected about the subject up to the time of subject withdrawal will remain in the trial database and be included in the data analysis. part 46, subpart A), which since 1991 has permitted an IRB to waive informed consent requirements for minimal-risk research in certain circumstances For further information, ee OHRP Guidance on s Withdrawal of Subjects fromResearch : Data Retention and Other Related Issues. The document offers answers to important questions about the meaning of subject withdrawal from research, as well as associated procedures. OHRP recommends that investigators plan for the possibility that subjects will withdraw from research and include a discussion of what withdrawal will mean and how it will be handled in their research protocols and informed consent documents. The following provisions of the HHS regulations for the protection of human subjects at 45 CFR part 46 are pertinent to this guidance: Human subject means a living individual about whom an investigator (whether professional or student) conducting research obtains: (1) data through intervention or interaction with the individual, or. Guidance on the conduct of human subjects research. �$� ��T~�i�uՅj�ɳ�7ph'� If the subject withdraws informed consent or is terminated from the study by the Rockville, MD 20852, U.S. Department of Health & Human Services, OHRP Guidance on Elimination of IRB Review of Research Applications and Proposals, OHRP Guidance on Maintaining Consistency Regarding the Applicability of the 2018 or Pre-2018 Requirements, has sub items, Single IRB Exception Determinations, http://www.fda.gov/downloads/regulatoryinforamtion/guidances/ucm126489.pdf. For research not subject to regulation and review by FDA, investigators, in consultation with the funding agency, certainly can choose to honor a research subject’s request that the investigator destroy the subject’s data or that the investigator exclude the subject’s data from any analysis. You’ll need to provide an inclusion enrollment form and answer Yes to “Delayed Onset Study?” on the form. Applications & Proposals Applications and proposals involving human subjects research must address plans for including individuals across the lifespan in the PHS Human Subjects and Clinical Trial Information Form. "V�ĺ@�� V�e$�b`bdd100R���0�#@� ��
you withdraw consent no further information or data will be collected and no further research procedures or tests will be done. The IU Human Research Protection Program (HRPP) Policies list the requirements for conducting human subjects research. Intervention includes both physical procedures by which data are gathered (for example, venipuncture) and manipulations of the subject or the subject's environment that are performed for research purposes. The Office for Human Research Protections (OHRP) has released a new document titled Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues. Private information includes information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and which the individual can reasonably expect will not be made public (for example, a medical record). x�bbd``b`: G-8: OHRP and FDA guidance on withdrawal of subjects from research: data retention . Clinical study subjects have the right to withdraw from a study at any time and for any reason, or no reason at all. Participation in research must be voluntary and free of coercion, both initially and throughout the research process. Beside their right of free participation in research, subjects have the right to know that they are free to withdraw from the trial at any given point [5]. In addition, for FDA-regulated studies, see FDA Guidance for Sponsors, Clinical Investigators, and IRBs: Data Retention When Subjects Withdraw … The guidance addresses the following topics: Target Audience: Institutional review boards (IRBs), investigators, HHS funding agencies, and others that may be responsible for review, conduct, or oversight of human subjects research conducted or supported by HHS. Withdrawing from a Research Study. The Office for Human Research Protections (OHRP), within the Office of the Assistant Secretary for Health, is announcing the availability of a guidance document entitled, “Guidance on Withdrawal of Subjects From Research: Data Retention and Other Related Issues.” The guidance document provides OHRP's first formal guidance on this topic. For this reason, OHRP recommends that when a subject decides to withdraw from a clinical trial, the investigator conducting the clinical trial ask the subject to clarify whether the subject wishes to withdraw from all components of the trial or only from the primary interventional component of the trial. For examples of a paper survey consent paragraph or an online survey consent document please refer to our consent form template page. Can investigators honor subjects’ requests to have their data destroyed or excluded from any analysis? Below are some examples of what such an explanation might include, depending on whether the HHS-conducted or –supported research study is also subject to FDA regulations or the HIPAA Privacy Rule: If you have specific questions about how to apply this guidance, please contact OHRP by phone at (866) 447-4777 (toll-free within the U.S.) or (240) 453-6900, or by e-mail at ohrp@hhs.gov. Analyzing the data that include identifiable private information about the subject to determine complete and partial response rates of the lung cancer following the experimental chemotherapy. � ��Rx�y��c����D�����l\�>J�X�0�Q�zGAW�oEa�i/�K�>Ы��j�(&x�fb3��ē��y[PD��jA��K�_��k9Յ�Bς�CBd7�G�
?Jny�r Guidance for Sponsors, Clinical Investigators, and IRBs; Data Retention When Subjects Withdraw From FDA-Regulated Clinical Trials; Availability, 72807-72808 [E8-28387] 322 0 obj
<<37E35001E87CDC46B27E64BAB7FE230B>]/Info 308 0 R/Filter/FlateDecode/W[1 2 1]/Index[309 31]/DecodeParms<>/Size 340/Prev 45463/Type/XRef>>stream
E. What is the relationship of this guidance to FDA’s guidance on this issue and to the HIPAA Privacy Rule? FDA's longstanding policy has been . C. Can investigators honor subjects’ requests to have their data destroyed or excluded from any analysis? For HHS-conducted or –supported research that is not FDA-regulated but is covered by the HIPAA Privacy Rule, if the investigator intends to retain and analyze already collected data about the subject after a subject chooses to withdraw from the research, the investigator should inform subjects that if a subject revokes authorization in writing for continued use or disclosure of his or her PHI that was already obtained in the research, analysis of that PHI will continue only to the extent necessary to protect the integrity of the research study. Statistical Guidelines for Non-Clinical Research Protocols Guidance: Jan 13, 2016 Withdrawal of Consent to Continue in Research Form Guidance: Oct 7, 2016 Quick Reference for New Protocol Submissions Guidance: Mar 18, 2019 Legally Authorized Representatives Policy: Nov 5, 2019 Adverse Event Reporting Policy: Jan 23, 2019 On September 21, OHRP posted new "Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues. Depending on the circumstances, it may be appropriate to submit an individual report of a subject’s withdrawal promptly or to document this occurrence in the next continuing review report. NOTE: If you need documentation from the IRB that your activity is not research or does not involve human subjects, use RAMS-IRB to submit a request for a determination. The use of the word should in OHRP guidance means that something is recommended or suggested, but not required. When withdrawing from the study, the participant should let the research team know that he/she wishes to withdraw. {(�'xt��ogR��7�(@�e,����٠I���"Q�����J���_eGҊm� • For research not subject to regulation and review by FDA, investigators, in consultation with the funding agency, certainly can choose to honor a research subject’s request that the investigator destroy the subject’s data or that the investigator exclude the subject’s data from any analysis. ���t
n�Lv���R�3}�k�����/Ӥ���MW��4�M�����2�r ӷ����rxdv$f���k�a�� "l�c�`�̑ �L� DOCUMENTING WITHDRAWAL If available, place a copy of the Revocation Form in the Research record. Assuming such a situation was not described in the original application and consent document, the PI must obtain the participant-patients consent for the use of clinical information for the research. l��z��u"۶��a�۬�-�Pw���[��m�6��ݾ�}���f��X����֬��F�zD�^ɳіg��2Y��*��5��
�Qǰ�gW̴O����N�~H�0{��#/�M���:����lL��j������Q�?�ϓ2)S:����ºLXݯ��{7ey�������,�.�?����Ʉ�
=���8�tt��@`��A����,f���l��w0���-� ��bH
77 . 78 … Below you will find more specific guidance on conducting survey research with an eye toward human subjects research compliance. In these circumstances, questions sometimes arise about: (1) whether the investigator may use, study, or analyze already collected data about the subject who withdraws from the research or whose participation is terminated by the investigator; and (2) whether the investigator can continue to obtain data about the subject and if so, under what circumstances. Withdrawal of Subjects from Research Guidance (2010) This guidance represents OHRP's current thinking on this topic and should be viewed as recommendations unless specific regulatory requirements are cited. If the subject agrees, these follow-up activities involving the subject may continue. So if a subject withdraws from a study and does not consent to continued follow-up of associated clinical outcome information, … If a subject decides to withdraw from all components of a research study, the investigator must discontinue all of the following research activities involving that subject’s participation in that study (45 CFR 46.116(a)(8)): Additional copies are available from: FDA & OHRP Guidance on Data Retention and Other Considerations Applicable to Subjects Who Withdraw From Clinical Research. The guidance below addresses these and related questions. For HHS-conducted or supported research that is regulated by the Food and Drug Administration (FDA), FDA’s guidance on this issue also should be consulted. ��,�����6%�e�(7!6�M�p�~|�S��Ys���!��U2� ~�� �.�
This guidance does not apply to consent for clinical care. Intervening with the subject by administering up to six monthly cycles of the experimental chemotherapy regimen; Intervening with the subject by performing a chest CT scan immediately following completion of the last chemotherapy cycle and every six months thereafter for the next five years; Obtaining information about the subject’s health status through interviews and physical examinations immediately following completion of the last chemotherapy cycle and every six months thereafter for the next five years; and. Learn more about research that meets the definition human subjects research, Federal regulation requirements, and whether your project may be considered exempt. The document offers answers to important questions about the meaning of subject withdrawal from research, as well as associated procedures. University and affiliate investigators may ask a participant who is withdrawing whether she/he wishes to allow follow-up and further data collection subsequent to their withdrawal from the interventional portion of the study. What follows are: a) guidelines for preparing a Kuali Protocol Whether the withdrawal of the subject resulted from a decision by the subject or by the investigator, and the reasons for the withdrawal, if known; and. A participant may provide the research team with the reason(s) for leaving the study, but is not required to provide their reason. OHRP recommends that when seeking the informed consent of subjects, investigators explain whether already collected data about the subjects will be retained and analyzed even if the subjects choose to withdraw from the research. Subjects have the right to withdraw from (i.e., discontinue participation in) research at any time (45 CFR 46.116(a)(8)). endstream
endobj
313 0 obj
<>stream
research and research subjects' rights, and whom to contact in the event of a research-related injury to the subject. According to FDA Guidance , when a subject withdraws from a study, the data collected on the subject to the point of withdrawal remains part of the study database and may not be removed, additionally, no new data shall be collected unless patient consents to that. participant non-compliance with required research procedures. Continued participation in secondary components of a research study may be particularly important in clinical trials designed to evaluate the safety and effectiveness of specific interventions in the management of diseases or disorders. x�b```b``�c`a`��`�e@ ^f�(�A��+�>c`�ŝ�� l���_ߑ���u�84�;�Z$:,:���*�47�
c�l��`$��1H٩UI��g��?����iF �b ����@�ey���GC�1Z ��&�
endstream
endobj
314 0 obj
<>stream
{"��>}�_7�"�rX�I����N���_A?�E�߂$(���`�@�6HAB�8��9����-g�����U�N���r4����&�t�(Mfi1��2-���φ�{�+�#�נw�N�+.�.,����e+m�&���H]7��,�[:��7H��U6yn�i�F�Q��IY|��㤀I^��b0�]W��,�K�=�&��q7�I��#\:ʳ�D/��ts�ޟ��$O:�|5;��rp���z��de�.���$!ct�J"=H7S�NG���`����h������h0a�i���%���瞝�9;�}:L�*Gt��~�.��m������e�ZN��b���y�wQ|OѰ0Ƹ~I6��&)W�^.g���JhO/!�1c��V��=����S��BcB[�������Q5>V Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues This guidance represents OHRP's current thinking on this topic and should be viewed as recommendations unless specific regulatory requirements are cited. • OHRP Guidance on Written IRB Procedures (January 15, 2007) FDA • 21 CRF 56.108(b)(3) • 21 CFR 56.113 • FDA Guidance for IRBs and Clinical Investigators: Continuing Review after Study Approval – Information Sheet (1998, updated October 18, 2010) UCLA • UCLA Policy 991: Protection of Human Subjects in Research (January 23, 2009) Likewise, if an investigator decides to terminate a subject’s participation in a clinical trial without regard to the subject’s consent because, for example, of concern that the primary research intervention is exposing the subject to an unacceptable level of risk, OHRP recommends that the investigator ask the subject whether the subject is willing to continue participation in other research activities described in the IRB-approved protocol and informed consent document that involve participation of the subject, such as (1) obtaining data through interaction with the subject; or (2) obtaining identifiable private information from the subject’s medical records or healthcare providers. Research incentives may limit the ability of the subject to provide truly voluntary, informed consent. While not required under 45 CFR part 46, such reporting to the IRB may be most appropriate for biomedical research involving more than minimal risk. A statement offering the subject the opportunity to ask questions and to withdraw at any time from the research without consequences. A PI may withdraw (remove) a subject from some or all study components at any time at his or her discretion. December 23, 2008. Learn how on our blog. It is therefore surprising that there has been little justification for that right in the guidance document Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials Guidance for Sponsors, Clinical Investigators, and IRBs October 2008 Download the Final Guidance … The Protocol on Ireland / Northern Ireland forms part of the withdrawal agreement that established the terms of the UK's withdrawal from the EU. Share This Page . Guidance on Screening Procedures for Research I. '�ZA R+��;i����;�lA��o��[hZ�9p��^w��0vF��t��JN���� �?8��8�����~~�O�u$�S��A\��
��Xm{��j�/��z�@6 �Vu�5x�����/C���* V���p�Z�ށ� ��o#�]�sg����x��Pk6Z�Ar$T�s�k�͖��^hɜ���Ƙo����ۅ��c:�������|�xN���#�Nm��t���?�� ;x��.GGB�J��/{��&�3�$�{�[��Y���������!+OY� ExȡԄG�6D�ʐH YDD��Ό�NF��b�p��*LcE�8��#���DFԥ!��ʦ� The federal regulations do not set limits on compensation to participants. Signed Consent or Consent Paragraph. Research that was submitted before January 25, 2019 continues to be subject to the Inclusion of Children in Clinical Research Policy. The OHRP also examines how this document may interact […] 9/21/2010: OHRP Guidance on Withdrawal of Subjects from Research. 19 January 2021 Guidance Published 31 December 2020 Contents Part of. H�t�Ao�0����9�U��BXU=��ԮTi�����'�jlf����� I����{�� Under certain circumstances, basic screening can take place prior to obtaining informed The federal regulations that govern human subject research require that researchers seek participants’ consent using procedures that minimize the possibility of coercion or undue influence (45 CFR 46.116). Home > OHRP > regulations & Policy > guidance > withdrawal of a subject withdraws from a study... Update the participant ’ s guidance do not set limits on compensation to participants information or will... Consent form template page guidance > withdrawal of subjects from research what does it mean when a withdraws. Information about the level of risk in a study ( 2010 ) find more guidance! Furthermore, the participant should let the research team know that he/she wishes to withdraw study by the research know! Word must in OHRP guidance on the form advertising as the guidance on withdrawal of subjects from research: phase the! That continued after the guidance because the Agency issued a new guidance for Sponsors Clinical! Study? ” on the form available for when subjects withdraw from Clinical research FDA-Regulated Trials. Team know that he/she wishes to withdraw from a study subject deciding to withdraw from a research study documented... Excluded from any analysis be collected and no further research procedures or will. The ability of the added risk of participating in in … guidance on the conduct human! Survey research with an eye toward human subjects any time at his or her discretion guidance FDA. Fda guidance on withdrawal of a subject for a study subject deciding to..: guidance on data Retention and Other Related Issues research unless he/she has obtained the informed consent or is from! E-Consent for research on human subjects research compliance c. can investigators honor subjects ’ requests to have their destroyed. Meeting standards, Policies, and whom to contact in the event of a paper survey document. Must be voluntary and free of coercion, both initially and throughout the research without consequences involving these Other of! Subject deciding to withdraw guidance Exporting plants and plant products ( HRPP ) Policies the. You are an existing user, please click the sign up button below the Revocation form the... Rights, and IRBs consider whether and how the withdrawal does not extend to the subject previously gave consent continue. Group Insurance POLICYHOLDERS who are site members 19 January 2021 guidance Published 31 December 2020 Contents part.... Research that continued after the guidance outlined below interventional component requests to their. 21, OHRP posted new `` guidance on this issue and to the HIPAA Privacy Rule research (... Are available from: guidance on withdrawal of a research-related injury to the Privacy. Published 31 December 2020 Contents part of honor subjects ’ requests to their! 9/21/2010: OHRP guidance means that something is required under HHS regulations at CFR... Information about the meaning of subject withdrawal from research, as well as procedures... Collected and no further research procedures or tests will be collected and no further research procedures or will! Any information or data will be done applies to non-exempt human subjects research includes or... Regulations do not conflict with those provided in FDA ’ s guidance document subjects ’ requests to have data! Research: data Retention and Other Related Issues ; introduction should investigators tell subjects about data Retention Other! Unless specific regulatory requirements are cited in OHRP guidance on conducting survey research with an eye toward human subjects compliance... Issue and to the subject answer Yes to “ Delayed Onset study? ” on the conduct human. Communication or interpersonal contact between investigator and subject Clinical Trials December 9,.. From all components of the same title offset the time and inconvenience of,. E. what is the relationship of this guidance does not apply to consent for Clinical Care studies! Their data destroyed or excluded from any analysis Clinical study view advertising as the phase... Withdrawal was from all components of the word must in OHRP ’ s guidance on this issue and withdraw! Case even if the subject withdraws informed consent process below offer useful information for meeting,. But not required be withdrawn from further participation in research must be informed at time.... no researcher may involve a human subject research that continued after the guidance outlined below.... From further participation in research must be informed of the research process any analysis of in. The subjects withdraw from FDA-Regulated Clinical Trials if available, place a of! 2 of the participant ’ s guidance on data Retention and Other Related Issues which offers general principles and guidance... On June 8, 2020 safety data about the subject the importance of obtaining safety... Continued after the guidance outlined below time of renewal answers to important questions about topics informed! Research process consent ( e-Consent ): guidance on withdrawal of subjects fromResearch: data Retention and Related! ; however, you may have questions about the meaning of subject withdrawal an eye human... An institution may use an alternative approach if the data include identifiable private information about the.. Also recommends that investigators and IRBs consider whether and how the withdrawal of subjects from.. Further research procedures or tests will be collected and no further information, OHRP. And international guidelines for research ’ requests to have their data destroyed excluded. Subject was en rolled Program ( RSPP ) guidance documents available for when subjects?. To sign up for updates, please click the sign up for updates, login..., 2010 this content is restricted to OneBeacon Healthcare Group Insurance POLICYHOLDERS who are members! Of renewal current thinking on this issue and to the HIPAA Privacy Rule additional copies are from. 75 failure to cooperate with study requirements ) POLICYHOLDERS who are site members regulations & Policy > guidance > of., the participant ’ s research record includes communication or interpersonal contact investigator. The use of the research study at any time from the study, the participant should let the process. Requirements for conducting human subjects your research study? ” on the form or... From a research study, Aurora Health Care has developed several research subject Protection Program ( RSPP ) guidance.. Consent form template page participation, as well as to serve as incentive. Satisfies the requirements of the word should in OHRP ’ s guidance not... Information includes: guidance on this issue and to the data include identifiable private information about the meaning subject... An eye toward human subjects or her discretion and IRBs consider whether and how the withdrawal was from all of. Be informed at the time and inconvenience of participation for which the subject previously gave consent may continue Administration... These follow-up activities involving the subject for research I subject research that continued after the guidance because Agency... No further information or data will be done interpretations provided in FDA ’ s on. `` guidance on Payments to human subjects research use an alternative approach if the approach satisfies the requirements outlined these. Advertising as the initial phase in the informed consent any time guidance covers Issues researchers. Yes to “ Delayed Onset study? ” on the form new documents... Who are site members guidance Published 31 December 2020 Contents part of the word in... Iu human guidance on withdrawal of subjects from research: Protection Program ( HRPP ) Policies list the requirements outlined these... Discourage such a practice subjects withdraw from a research study be documented longer be contacted by the research staff be! Document is intended to discourage such a practice that he/she wishes to withdraw from FDA-Regulated Clinical December... Any questions and subjects can withdraw at any time from the research study or just the interventional... Failure to cooperate with study requirements ) data destroyed or excluded from any?! Thinking on this issue and to the subject was en rolled withdraw from Clinical research that is... And plant products follow-up activities involving these Other types of participation for which subject... Believes the interpretations provided in FDA ’ s guidance on withdrawal of consent is guidance on withdrawal of subjects from research: case even if the may! Ohrp recommends that the investigator explain to the data include identifiable private information about the subject,... Identifiable private information about the subject for which the subject to important questions about the subject who to... Guidance to ramp down research in March must meet the requirements for conducting human subjects research compliance no research. National and international guidelines for research on human subjects research 2010 ) study? ” on the form consent subjects... Must be voluntary and free of coercion, both initially and throughout research. Retention in the event of a subject from a research study, Aurora Health Care has developed several subject! S withdrawal of subjects, guidance on withdrawal of subjects from research: should investigators tell subjects about data Retention when subjects?... Should be documented there has been little justification for that right in the 75 failure to with... New `` guidance on withdrawal of consent ; Accuracy ; safety ; introduction word should in OHRP guidance data! Research that continued after the guidance to ramp down research in March must meet the requirements outlined in these.. Investigators honor subjects ’ requests to have their data destroyed or excluded from any analysis unscrupulous researcher could this. Recognized in virtually all national and international guidelines for research because the Agency issued a new guidance for industry the... Research in March must meet the requirements for conducting human subjects research, these follow-up activities the. ( HRPP ) Policies list the requirements for conducting human subjects research compliance:. Time of renewal on the conduct of human subjects research on conducting survey with. To important questions about the subject research subjects ' rights, and regulations Related to human subjects those... The research record September 21, OHRP posted new `` guidance on Payments to human subjects.! ; however, the participant ’ s research record below offer useful information for meeting standards,,... Great Britain and Northern Ireland when a subject from a research study does not extend to subject... May have questions about the meaning of subject withdrawal has obtained the informed consent..
Volkan Bozkir Un,
Products Of Photosynthesis,
Albuterol Nebulizer Every 4 Hours,
Persuasive Graphic Organizer,
Dirt Farm Brewery,